Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol - Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Kütüphanede Ara Ara
Altai Protocol Library

New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study:
  • Randomised, triple-blind, phase 3 trial
  • Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC
  • Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles
Efficacy:
  • mDFS: 53.6 m vs 42.0 m (HR 0.76 [95% CI 0.63–0.91], p=0.0014)
  • mDFS: NR vs NR in the PD-L1 TPS of 50% or greater population (HR 0.82 [95% CI 0.57–1.18]; p=014).
  • 3 year OS: 82% vs %80
Safety:
  • Any grade AEs: 96% vs 91%
  • Grade ≥3 AEs: 34.7% vs 26.8%
  • Discontination due to adverse events: 20% vs 6%
  • Death due to adverse events: 2% vs 1%

Lancet Oncol. 2022 Sep 9;S1470-2045(22)00518-6.

O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

https://doi.org/10.1016/s1470-2045(22)00518-6

Reviewed by Hasan Çağrı Yıldırım, MD on Sep 28, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More